Related Experiment Videos
Proton-driven dipeptide uptake in primary cultured rabbit conjunctival epithelial cells
S K Basu1, I S Haworth, M B Bolger
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles 90033, USA.
Investigative Ophthalmology & Visual Science
|November 6, 1998
Summary
This study reveals a proton-driven transporter for beta-alanyl-L-histidine (L-carnosine) in rabbit conjunctival cells. This transporter may be key for delivering peptidomimetic drugs to the eye.
Area of Science:
- Ocular pharmacology
- Membrane transport
- Biochemistry
Background:
- Conjunctival epithelial cells play a crucial role in ocular drug absorption.
- Dipeptide uptake mechanisms are vital for ocular drug delivery and efficacy.
- L-carnosine serves as a model dipeptide substrate for transport studies.
Purpose of the Study:
- To characterize the proton-driven, carrier-mediated uptake of L-carnosine in rabbit conjunctival epithelial cells.
- To investigate the kinetic properties and substrate specificity of the dipeptide transporter.
- To explore the potential of this transporter for peptidomimetic drug delivery.
Main Methods:
- Primary conjunctival epithelial cells from pigmented rabbits were cultured.
- Tritiated L-carnosine uptake was measured under various conditions (pH, inhibitors, temperature).
- Computer modeling and stereoisomer inhibition studies evaluated transporter interaction.
Main Results:
- L-carnosine uptake demonstrated directional asymmetry, pH optimum (6.0), and Michaelis-Menten kinetics (Km = 0.3 mM, Vmax = 22.0 pmol/mg protein/min).
- Uptake was inhibited by proton ionophores and NH4Cl, indicating proton dependency.
- Structurally similar dipeptides and drugs inhibited uptake, suggesting transporter promiscuity.
Conclusions:
- A proton-driven dipeptide transporter mediates L-carnosine uptake in conjunctival cells.
- This transporter exhibits characteristics suitable for the delivery of peptidomimetic drugs.
- Understanding this transporter can optimize ocular drug development.